Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.67 |
| ▸ | CTSL | P07711 | 8/20 | 0.67 |
| ▸ | CTSK | P43235 | 6/20 | 0.67 |
| ▸ | CTSB | P07858 | 1/20 | 0.67 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.44 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.43 |
| ▸ | PADI2 | Q9Y2J8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5525446 | 0.84 | CTSS (0.78) | CTSSCTSLCTSKCTSBCHRNB2 | |
| SCHEMBL5522191 | 0.84 | TAS1R3 (0.48) | CTSSCTSLCTSKCTSBTAS1R3 | |
| SCHEMBL14283702 | 0.82 | TAS1R3 (0.68) | CTSSCTSLCTSKCTSBTAS1R3 | |
| SCHEMBL5518266 | 0.82 | CTSL (0.85) | CTSSCTSLCTSKCTSBCHRNB2 | |
| SCHEMBL5520437 | 0.82 | CTSL (0.85) | CTSSCTSLCTSKCTSBCHRNB2 | |
| SCHEMBL5530385 | 0.81 | CTSL (0.79) | CTSSCTSLCTSKCTSBCHRNB2 | |
| SCHEMBL5522179 | 0.81 | CTSL (0.83) | CTSSCTSLCTSKCTSBCHRNB2 | |
| SCHEMBL5521614 | 0.81 | CTSL (0.83) | CTSSCTSLCTSKCTSBCHRNB2 | |
| SCHEMBL5530445 | 0.81 | CTSL (1.00) | CTSSCTSLCTSKCTSBCHRNB2 | |
| SCHEMBL6875796 | 0.81 | CTSL (1.00) | CTSSCTSLCTSKCTSBCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015755-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| US-20040147745-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | US | disclosed |
| EP-1178958-B1 | N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS | AXYS PHARM INC (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030096796-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-05-22 | — | — | US | disclosed |
| US-6455502-B1 | Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096796-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | CTSS 10/4885CTSL 14/4885CTSK 32/4885 |
| US-20040147745-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | CTSS 10/4885CTSL 14/4885CTSK 32/4885 |
| US-20070015755-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | CTRL, SERPINB1, CPN1 | CTSS 10/4885CTSL 14/4885CTSK 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.